Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Delota Corp. (SYDRF)
Concord, ON, CA
Delota Corp. operates as a Canadian retail company, primarily focusing on the sale of diverse cannabis products. Their product range also encompasses various vaping and nicotine-related items, herbal vaporizers, and other smoking cessation solutions, along with their complementary accessories. The firm manages a network of 26 brick-and-mortar retail establishments complemented by an online e-commerce platform. These operations are conducted under its two prominent brands: 180 Smoke and Offside Cannabis. The company, which is headquartered in Concord, Canada, transitioned its name to Delota Corp. in November 2021, having previously been recognized as Spyder Cannabis Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +25.00% | +8.93% | -35.53% | -35.53% | -35.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%+18.0% ★ Q4'25: -18.4% (vs Q4'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%+126.3% ★ Q4'25: -187.5% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+4.5% Q4'25: -2.2% (vs Q4'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.9% Q4'25: -4.2% (vs Q4'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+36.6% ★ Q4'25: -29.3% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+6.9% Q4'25: -1.7% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.84× Q4'25: 41.23× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Cameron-Takehiko Wickham | Executive Vice Chairman, Chief Executive Officer & Corporate Secretary | 92.7K | male |
| Daniel Pelchovitz | Director & Chief Executive Officer of Cannabis Division | 84.2K | male |
| Ankit Gosain | Chief Financial Officer | 70.9K | male |
| Mark Pelchovitz | Executive Chairman | 35.5K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYDRF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
